Patient Perspectives on Toxicities Associated with Standard- and High-Dose Radiotherapy for Prostate Cancer

Recipients of standard- and high-dose radiotherapy reported similar rates of long-term urinary, bowel, and sexual-dysfunction symptoms.

Evidence is slowly accumulating to support the benefits of high-dose radiotherapy in patients with localized prostate cancer. Nonetheless, the potential to improve patient outcomes must be balanced against the risks for short- and long-term toxicities related to therapy. Although such toxicities usually are reported in the form of physicians' assessments, patient reports of toxicity tend to be more reliable.

Investigators conducted a post hoc analysis of patient-reported toxicities among participants in the Proton Radiation Oncology Group (PROG) 9509 trial (JW Oncol Hematol Mar 2 2010). All patients had localized prostate cancer and received conformal photon (x-ray) therapy at a fixed dose of 50.4 Gy plus proton boost doses of either 19.8 Gy…

Reviewing Author

Robert Dreicer, MD, MS, FACP

Disclosures

Consultant/Advisory BoardAstellas; Aveo; Bayer; Gilead; Merck; Pfizer; Propella; Macrogenics

Editorial BoardsCurrent Urology Reports

Robert Dreicer, MD, MS, FACP

Disclosures

Consultant/Advisory BoardAstellas; Aveo; Bayer; Gilead; Merck; Pfizer; Propella; Macrogenics

Editorial BoardsCurrent Urology Reports